Skip to content
March 28, 2024

Equity.Guru

Investment information for the new generation

Search

FH.NE

Counting to Four $25.537M Market Capitalization  Filament Health Corp. (FH.NE) announced today that it has been issued a fourth patent for the extraction and standardization of natural psilocybin and…
Natural Psychedelics Revolution $21.418M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has entered into an exclusive licensing agreement with Psyence Group Inc. (PSYG.C). Under the terms…
Patent Issuance $18.123M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has been issued a patent by the United States Patent and Trademark Office (USPTO) for the…
A Transformative Year $18.123M Market Capitalization Filament Health Corp. (FH.NE) today released its Q4 2021 financial results and has provided operational highlights for the period ended December 31, 2021….
Natural Talent Albert Hofmann was a fun guy, pun intended. More importantly, the Swiss chemist is known for being the first person to synthesize, consume, and learn of the psychedelic…
Problematic Psychedelics? Psychedelics and mental health treatment go together like orange juice and toothpaste. That’s what I would have said five years ago. Prior to the publication of multiple…
Filament Health (FH.NE) has released two new press releases since the last time I covered the company back in mid January 2022. Filament Health Corp. operates as a natural psychedelic…
Filament Health (FH.NE) announced today that it has received approval from Health Canada for a Phase 2 clinical trial using PEX010, the Company’s botanical psilocybin drug candidate. Cybin Therapeutics…
I’ll admit that I’m beginning to have my suspicions about the psychedelic sector. The question I’ve started asking when I look at a new psychedelics company is where’s the…
You’d be hard pressed to find someone who hasn’t been touched by depression or anxiety. Biochemically, they’re considered co-morbid, which means they often happen at the same time and…